Axel Schörling
Fortuna: 1 M $ al 31/05/2026
Fortuna: 1 M $ al 31/05/2026
Axel Schörling is President & Chief Executive Officer at EQL Pharma AB since 2022 and Independent Director at Gasporox AB since 2023.
Formerly, Mr. Schörling was Director-Business Controlling at Perstorp AB. Mr. Schörling graduated from Chalmers University of Technology and Handelshögskolan i Göteborg.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
EQL PHARMA AB 1,36 % | 27/03/2026 | 401.445 ( 1,36 % ) | 1 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| EQL PHARMA AB | Director Ejecutivo | 17/08/2022 |
| GASPOROX AB | Director/Miembro de la Junta | 01/01/2023 |
| Empresas | Cargo | Fin |
|---|---|---|
| PERSTORP HOLDING AB (PUBL.) | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
Perstorp AB
Perstorp AB Chemicals: SpecialtyProcess Industries Manufactures and supplies specialty chemicals | Process Industries |
Chalmers University of Technology
Chalmers University of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gasporox AB
Gasporox AB Miscellaneous Commercial ServicesCommercial Services Provides laser technology and aims to benefits from non-intrusive diode laser spectroscopy technology | Commercial Services |
Handelshögskolan i Göteborg
Handelshögskolan i Göteborg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
EQL Pharma AB
EQL Pharma AB Pharmaceuticals: GenericHealth Technology Manufactures and distributes generic and specialty pharmaceutical products | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.